» Articles » PMID: 20707839

Evaluation of a Quality-of-life Tool for Cats with Diabetes Mellitus

Overview
Date 2010 Aug 17
PMID 20707839
Citations 40
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Success in management of diabetes mellitus (DM) is defined as improvement of blood glucose concentrations and clinical signs. However, the psychological and social impact of DM and its daily treatment regimen on quality of life (QoL) of both animal and owner is uncertain.

Hypothesis/objectives: To design, validate, and apply a diabetic pet and owner-centered, individualized measure of impact of DM (DIAQoL-pet). ANIMALS/SUBJECTS: Two hundred and twenty-one owners of insulin-treated diabetic cats were recruited to complete the DIAQoL-pet.

Methods: Discussions and pilot surveys with clinicians and owners of diabetic cats led to the design of 29 specific DM-associated QoL questions. Owners of diabetic cats completed the finalized survey. Each item was scored according to impact frequency and perceived importance. An item-weighted impact score (IWIS) for each item was calculated, as was an average-weighted impact score (AWIS) by averaging all IWISs. Principal component analysis and Cronbach's α calculation assessed the measure's reliability. Two overview questions measured overall QoL and diabetes-dependent QoL.

Results: The DIAQoL-pet showed high reliability (Cronbach α 0.83). The AWIS was -1.76 ± 2.4 (mean ± SD). Areas reported as most negatively impacting QoL included: "boarding difficulties" (IWIS ± SD: -4.67 ± 5.3), "owner wanting more control" (-4.34 ± 4.7), "difficulties leaving cat with friends or family" (-4.21 ± 4.7), "worry" (-4.10 ± 3.9), "worry hypo" (-3.67 ± 3.5), "social life" (-3.48 ± 3.9), "costs" (-3.04 ± 3.8), and "work life" (-3.03 ± 3.7). Forty-one percent of owners believed their cat's life would be "a little better" without DM.

Conclusions And Clinical Importance: The DIAQoL-pet proved robust and identified specific areas most negatively impacting on diabetic cats and their owners' QoL. This tool warrants further investigation for use in clinical or research settings.

Citing Articles

Transmucosal glucagon rapidly increases blood glucose concentration in healthy cats.

Cohen E, Porter L, Crews C, Mott J, Tardo A, Gilor C J Feline Med Surg. 2024; 26(11):1098612X241280516.

PMID: 39614598 PMC: 11607742. DOI: 10.1177/1098612X241280516.


Life with pets study: lower income veterinary clients' perception of pets' quality of life.

Strand E, Scoresby K, Walker H, Hernandez A, Accornero V, Messinger L Front Vet Sci. 2024; 11:1422359.

PMID: 39086764 PMC: 11288882. DOI: 10.3389/fvets.2024.1422359.


SGLT2 inhibitor use in the management of feline diabetes mellitus.

Cook A, Behrend E J Vet Pharmacol Ther. 2024; 48 Suppl 1():19-30.

PMID: 38954371 PMC: 11736986. DOI: 10.1111/jvp.13466.


Efficacy and safety of once daily oral administration of sodium-glucose cotransporter-2 inhibitor velagliflozin compared with twice daily insulin injection in diabetic cats.

Niessen S, Kooistra H, Forcada Y, Bjornvad C, Albrecht B, Roessner F J Vet Intern Med. 2024; 38(4):2099-2119.

PMID: 38884190 PMC: 11256146. DOI: 10.1111/jvim.17124.


Development and validation of a quality of life and treatment satisfaction measure in canine osteoarthritis.

Gildea E, Scales-Theobald E, Thompson J, Cook A, Forde K, Skingley G Front Vet Sci. 2024; 11:1377019.

PMID: 38764853 PMC: 11100416. DOI: 10.3389/fvets.2024.1377019.